Pelareorep

Published

dm+d

Unassigned

New Medicines

ReolysinMetastatic, HER2-negative, hormone receptor-positive breast cancer

Information

Reolysin
New molecular entity
Oncolytics Biotech
Oncolytics Biotech

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

A first-in-class immuno-oncolytic virus (IOV) using a non-pathogenic, proprietary isolate of unmodified reovirus. Reolysin selectively replicates in permissive cancer cells which then lyse/die, releasing virus particles to infect nearby cancer cells.
In 2012, the estimated age-adjusted annual incidence of breast cancer in 40 European countries was 94.2 per 100,000 and the mortality 23.1 per 100,000. Approximately 4-6% of breast cancers are metastatic at diagnosis [1].
Metastatic, HER2-negative, hormone receptor-positive breast cancer
Intravenous